WHO closes 2025 with 96 countries measles-free and a warning about new vaccine financing
The year-end immunization summary reports 88% fewer measles deaths since 2000, malaria vaccine in 24 African countries, and 25 years without wild polio in the Western Pacific.
WHO's immunization department published its year-end summary on 18 December, and read as a scoreboard it is a good year. Read as a forecast, it is a set of programmes whose next phase depends on financing that is not yet secured [s1].
The message was issued by Kate O'Brien, Director of the Department of Immunization, Vaccines and Biologicals at WHO [s1].
What moved
Measles. Global measles deaths have fallen 88% since 2000, and 96 countries have now eliminated endemic measles [s1]. Three African nations were newly verified as having done so during the period: Cabo Verde, Mauritius and Seychelles [s1].
Elimination in this context is a technical status — interruption of endemic transmission, verified by a regional commission — not the absence of cases. Countries with elimination status still record importations and outbreaks. What the status certifies is that sustained chains of local transmission have stopped.
Malaria. Twenty-four African countries now offer malaria vaccines through their childhood immunization programmes, targeting more than 10 million children annually, and manufacturers have announced future price reductions [s1].
That number is the more consequential one in the summary. Malaria vaccine introduction went from pilot programmes to two dozen national schedules in a short span, and the constraint on the next expansion has been price and supply rather than evidence.
Polio. The Western Pacific Region marked 25 years without indigenous wild poliovirus [s1].
Yellow fever. The global emergency stockpile has been maintained at 6 million doses, and more than 38 million people have been protected through mass campaigns [s1].
HPV. Gavi-supported countries reached the milestone of 86 million girls vaccinated by the end of 2025 [s1], a figure tied to cervical cancer elimination targets.
Meningitis. WHO released its first-ever global guidelines for meningitis diagnosis, treatment and care during the period, alongside progress toward a Group B Streptococcus vaccine, and member states reaffirmed the "Defeating Meningitis by 2030" roadmap [s1].
The part that is about money, not medicine
The summary also records that WHO issued guidance calling for "bold, coordinated action to ensure financing and equitable access" to anticipated new tuberculosis vaccines now in advanced clinical trials [s1].
That phrasing is worth noticing, because it is pre-emptive. There is no licensed TB vaccine for adults and adolescents yet; the candidates are still in trials. WHO is issuing access guidance before there is a product to allocate.
The reason is the pattern the last two decades established. New vaccines reach high-income markets first, and the interval before they reach the countries with the highest burden has historically been measured in years — sometimes more than a decade. For tuberculosis, where the burden is almost entirely in low- and middle-income countries, a repeat of that pattern would make a successful vaccine nearly useless for most of its first years of existence.
The same logic sits under the malaria note. Manufacturers announcing future price reductions [s1] is the mechanism by which the 24-country figure becomes a larger one; without it, the constraint holds.
How to read a year-end summary from an agency about its own programmes
Two caveats belong here.
First, this is WHO reporting on WHO-supported work. It is a primary source for what the agency counts as its results, and it is not an independent evaluation. The figures — 96 countries, 88%, 24 countries, 86 million girls — are the agency's own.
Second, cumulative progress figures measured from 2000 do not describe the current trajectory. An 88% reduction in measles deaths since 2000 is compatible with recent years being flat or worse; the baseline is a quarter-century old. Nothing in a "since 2000" figure tells you what happened in 2025.
That matters this year in particular, given the contraction in external health assistance to low- and middle-income countries. A year-end summary built on cumulative milestones is structurally poor at showing a downturn in progress, because milestones are ratchets — a country verified as measles-free stays on the list.
What to watch
Whether malaria vaccine price reductions materialise and how far the 24-country figure moves in 2026. Whether TB vaccine access arrangements are agreed before, rather than after, licensure. Whether the countries newly verified measles-free hold that status through the next outbreak season. And whether the next reporting cycle publishes annual coverage figures alongside the cumulative ones, which is the only way to see whether progress is still progressing.
Sources
- [s1] World Health Organization, "Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO — November/December 2025," 18 December 2025. https://www.who.int/news/item/18-12-2025-message-by-the-director-of-the-department-of-immunization--vaccines-and-biologicals-at-who---november-december-2025
Sources
- Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO — November/December 2025 — World Health Organization , December 18, 2025
More on
Childhood vaccination coverage nearly doubled since 1980 — and has stalled since 2010
A Global Burden of Disease analysis of 204 countries finds 15.7 million children received no DTP dose in 2023, more than half of them in eight countries, and only one of three target vaccines on track for 2030.
Measles is spreading in 91% of Bangladesh's districts after a two-year vaccine stockout
WHO reports 19,161 suspected cases and 166 deaths in a single month, most in children under five. The country had been close to eliminating the disease.
Lebanon investigated only 52% of suspected measles cases adequately, a review finds
An analysis of a decade of surveillance data shows the system leans heavily on hospitals and misses cases in the community — the weakness that lets measles circulate undetected between outbreaks.
Malaria vaccine rollout averted about one in eight child deaths in three countries
A Lancet evaluation of the RTS,S introduction in Ghana, Kenya and Malawi reports a 13% drop in mortality among vaccine-eligible children — achieved with third-dose coverage of 71% and fourth-dose uptake under 40%.